(Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK’s blood cancer drug, Blenrep, in combination with other treatments, the company said on Thursday, paving the way for a relaunch of the drug after three years.
(Reporting by Padmanabhan Ananthan and Mariam Sunny in Bengaluru; Additional reporting by Bhanvi Satija in London; Editing by Maju Samuel)
Comments